Acorda may delay results from Fampridine trial until October

By Elaine Rigoli

Tampa, Fla., July 12 - Acorda Therapeutics, Inc. said it is updating the time period in which it expects to report results from its phase 3 clinical trial in Fampridine-SR, the company's lead product candidate for improvement of walking ability in multiple sclerosis patients.

Acorda said it now expects to report results from this clinical trial in late September or October. The results were originally expected in the third quarter of 2006.

The primary endpoint of the study is improvement in walking ability; secondary endpoints are measured leg strength and muscle spasticity.

Acorda is a commercial-stage biopharmaceutical company based in Hawthorne, N.Y.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.